SCHEDULE 13D: AEON Biopharma Director Robert Palmisano Discloses 5.7% Stake Through Family LLC

Robert J. Palmisano, a director of AEON Biopharma, Inc., and The Palmisano Family, LLC, have disclosed beneficial ownership of 2,265,000 shares, representing a 5.7% stake in the company's Class A Common Stock.

Summary

• Robert J. Palmisano, a director of AEON Biopharma, Inc., and The Palmisano Family, LLC, have filed a Schedule 13D disclosing beneficial ownership of 2,265,000 shares of AEON Biopharma's Class A Common Stock.
• This stake represents approximately 5.7% of the company's outstanding shares, based on 39,970,693 shares outstanding as of November 11, 2024.
• The shares were acquired by The Palmisano Family, LLC through pro rata distributions from Priveterra Sponsor, LLC.
• Specifically, 1,115,000 shares were received on July 19, 2024, and an additional 1,150,000 shares were received on July 25, 2024.
• The original source of funds for The Palmisano Family, LLC's membership in Priveterra was cash on hand in 2021.
• The stated purpose of holding these shares is for investment purposes, with the possibility of purchasing additional shares or disposing of existing ones depending on market conditions.
• Mr. Palmisano also holds an RSU Award for 36,021 shares of Class A Common Stock granted on August 31, 2024, which vests on the second anniversary of the grant date and is not included in the 13D beneficial ownership calculation as it does not vest within 60 days.

Sentiment

Score: 7

Explanation: The disclosure of a significant insider stake, particularly by a director, is generally viewed positively as it aligns management interests with shareholders. The stated purpose for investment suggests confidence, though the possibility of future sales is also noted.

Positives

• A director of AEON Biopharma, Robert J. Palmisano, holds a significant beneficial ownership stake of 5.7% in the company, aligning his interests with shareholders.
• The filing indicates a long-term investment intent, as the shares were acquired through distributions from a 2021 investment.

Future Outlook

The reporting persons hold their shares for investment purposes and may, depending on market conditions, purchase additional shares or dispose of some or all of their holdings. Robert J. Palmisano may also acquire additional securities in connection with his services as a director.

Management Comments

• "The Palmisano Family, LLC holds its shares of Common Stock for investment purposes."
• "The Palmisano Family, LLC may, from time to time, depending on market conditions and other considerations, purchase additional shares or dispose of some or all of the shares held by The Palmisano Family, LLC."
• "Mr. Palmisano has in the past acquired, and may in the future acquire, shares, stock options, RSUs or other rights to purchase securities of the Company in the ordinary course of business in connection with his services as a director of the Company."

Industry Context

This filing is a standard disclosure of a significant ownership stake by an insider (director) and does not inherently provide broader industry context. It indicates an insider's continued investment in the biopharmaceutical sector, specifically in AEON Biopharma.

Related Party Transactions

• The Palmisano Family, LLC received shares through pro rata distributions from Priveterra Sponsor, LLC, where Robert J. Palmisano is the sole manager of The Palmisano Family, LLC and a director of the Issuer. This indicates a transaction involving entities related to a director.

Stakeholder Impact

• Shareholders: The disclosure of a director's significant stake may instill confidence due to aligned interests, but the possibility of future sales could introduce uncertainty.
• Management: Robert J. Palmisano's role as a director and significant shareholder reinforces his commitment to the company's performance.

Next Steps

• The Palmisano Family, LLC may purchase additional shares or dispose of existing shares based on market conditions.
• Robert J. Palmisano may acquire additional securities (shares, options, RSUs) in connection with his director services.
• The RSU Award granted to Mr. Palmisano on August 31, 2024, is expected to vest on its second anniversary, subject to continued service.

Key Dates

Recommendation

Keywords

AEON Biopharma, Schedule 13D, Robert J Palmisano, Beneficial Ownership, Class A Common Stock, SEC Filing, Investment Stake, Director Ownership, Priveterra Sponsor LLC